AREXVY (respiratory syncytial virus vaccine, adjuvanted) GLAXOSMITHKLINE Indications: AREXVY is indicated for active immunisation for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus in individuals 60 ...

EXKIVITY (mobocertinib) TAKEDA Indications: EXKIVITY is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, ...

Tuberculosis (TB) is caused by the infection of mycobacterium tuberculosis (Mtb). In developing countries, co-infection of Mtb and HIV are common, as HIV could exacerbate TB. Nevertheless, the reverse impact of Mtb infection on HIV development has r...

Exkivity® ( mobocertinib ) 1-3 Takeda Mobocertinib is a kinase inhibitor of the epidermal growth factor receptor (EGFR) that selectively inhibits and irreversibly binds to EGFR exon 20 insertion mutations at lower concentrations than Wild type (...

The POEMS syndrome is a rare plasma cell disorder involving pathological changes of polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes. The diagnostic and therapeutic management of the disease is clinically challenging. Given ...